FREMONT, Calif., July 14, 2026 /PRNewswire/ -- THINK Surgical, Inc., a leading innovator of orthopedic surgical robots, today announced it has entered into a debt facility with Symbiotic Capital which will provide up to $65 million of growth capital. The facility provided an initial funded tranche of $25 million, with an additional $15 million based on achievement of certain milestones, and up to $25 million of discretionary capital.
THINK Surgical Secures up to $65 Million of Growth Capital
2 min read Premium comments
TMINI Miniature Robotic SystemTHINK Surgical, Inc.Symbiotic Capitalgrowth capitaldiscretionary capitalorthopedic surgical robotsdebt facility
TMINI Miniature Robotic System
Symbiotic Capital
The proceeds will be used by THINK to continue to advance its dual channel commercial strategy for its TMINI® Miniature Robotic System, which is currently compatible with approximately 70% of the market share for total knee implants.1
Stuart Simpson, President, and Chief Executive Officer of THINK Surgical said "This facility, combined with recent additional investments by our existing investors, will allow us to continue our significant growth and development of TMINI, and is expected to fully finance the Company to profitability."
"We are excited about TMINI's potential to advance surgical robotics in the field of orthopedics, and we are impressed by the compelling value proposition it offers to both physicians and patients," said Himani Bhalla, Senior Managing Director and Chief Investment Officer of Symbiotic Capital.
Piper Sandler served as financial advisor to THINK on the transaction.
About THINK Surgical, Inc.
THINK Surgical, Inc., is a privately held U.S.-based technology innovator that develops and markets orthopedic robots. THINK Surgical robots are open platforms providing support for implant brands from multiple manufacturers, enabling the choice of implant to be driven by the surgeon.
THINK Surgical actively collaborates with healthcare professionals around the globe to refine our orthopedic products, improving the lives of those suffering from advanced joint disease with precise, accurate, and intelligent technology. Please refer to the instructions for use for the TMINI Miniature Robotic System for a complete list of indications, contraindications, warnings, and precautions. For additional product information, please visit www.thinksurgical.com.
THINK Surgical and TMINI are registered trademarks of THINK Surgical, Inc.
About Symbiotic Capital (symbcap.com)
Symbiotic Capital is a healthcare credit firm that brings together decades of experience across healthcare, finance, and entrepreneurship. Our integration into a global healthcare ecosystem empowers us to provide lending solutions to fuel the growth of established healthcare companies around the world.
Healthcare Credit. For Science, By Science.
For more information, please visit www.symbcap.com.
Information repurposed from THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT® published by ORTHOWORLD® Inc.
Media Contact:
THINK Surgical Inc.
Jonathan Gibson
jgibson@thinksurgical.com
SOURCE THINK Surgical, Inc.
Why This Matters
Two Perspectives
MBA Lens: Economic and industry impact
THINK Surgical secured up to $65 million in growth capital from Symbiotic Capital, with an initial $25 million tranche. This funding will advance the dual-channel commercial strategy for its TMINI Miniature Robotic System, which is compatible with approximately 70% of total knee implants. The company aims for profitability, leveraging this capital and existing investor support to drive significant growth and development.
- The debt facility provides structured capital, including an initial $25 million, milestone-based $15 million, and $25 million discretionary funds, complementing existing investor investments.
- The strategy focuses on expanding the TMINI system's market penetration through its dual-channel approach, capitalizing on its broad compatibility with major knee implant brands.
PhD Lens: Clinical and outcomes impact
THINK Surgical's TMINI Miniature Robotic System is an orthopedic surgical robot designed as an open platform, supporting implant brands from multiple manufacturers. This technology aims to improve the lives of patients suffering from advanced joint disease by providing precise, accurate, and intelligent surgical assistance. The company collaborates with healthcare professionals to refine its products.
- The TMINI system is an orthopedic surgical robot featuring an open platform, allowing compatibility with diverse implant brands based on surgeon choice.
- Its primary clinical objective is to enhance surgical precision and accuracy for advanced joint disease, contributing to improved patient outcomes.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.